Royalty ups trans-Atlantic takeover bid for Elan to potential $8bn
This article was originally published in Scrip
Royalty Pharma has upped its hostile bid for Irish drug company Elan once again to $13 per share and has added a contingent value right offering shareholders the upside on sales of MS drug Tysabri.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.